Sanofi to replace entire Medivation board to drive sale, according to reports
Reports have emerged that Sanofi is looking to step up its efforts to take over oncology firm, Medivation, as it set to propose eight new members to the board.
The current board at Medivation have strongly opposed a sale, claiming that Sanofi’s offer “significantly undervalues” the company. Last week, Sanofi CEO Olivier Brandicourt wrote a letter to the board indicating that they would take steps to remove the board at Medivation if they refused to engage on a potential deal.
Sanofi is set to be receiving advice on their approach to the takeover from Goldman Sachs and Morgan Stanley.
Pfizer are also said to be actively pursuing a deal for Medivation, as they continued to source advice from Goldman Sachs.
To read our feature on why Medivation is so highly sought, please click here.
Sanofi and Regeneron have announced results from the second investigational phase 3 NOTUS trial for …
Sanofi has shared new data for the long-term efficacy of Nexviazyme (avalglucosidease alfa) for the …